W

WuXi XDC Cayman Inc
HKEX:2268

Watchlist Manager
WuXi XDC Cayman Inc
HKEX:2268
Watchlist
Price: 25.55 HKD 1.79% Market Closed
Market Cap: 30.6B HKD
Have any thoughts about
WuXi XDC Cayman Inc?
Write Note

WuXi XDC Cayman Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

WuXi XDC Cayman Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
W
WuXi XDC Cayman Inc
HKEX:2268
Net Income (Common)
ÂĄ283.5m
CAGR 3-Years
121%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Net Income (Common)
ÂĄ8.5B
CAGR 3-Years
30%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Net Income (Common)
ÂĄ1.9B
CAGR 3-Years
10%
CAGR 5-Years
34%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Net Income (Common)
ÂĄ2.6B
CAGR 3-Years
-2%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Net Income (Common)
ÂĄ958.7m
CAGR 3-Years
-24%
CAGR 5-Years
7%
CAGR 10-Years
24%
Genscript Biotech Corp
HKEX:1548
Net Income (Common)
-$177m
CAGR 3-Years
1%
CAGR 5-Years
-52%
CAGR 10-Years
N/A
No Stocks Found

WuXi XDC Cayman Inc
Glance View

Market Cap
30.6B HKD
Industry
Life Sciences Tools & Services

WuXi XDC Cayman Inc is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Wuxi, Jiangsu and currently employs 1,113 full-time employees. The company went IPO on 2023-11-17. WuXi XDC Cayman Inc is a holding company primarily engaged in the provision of contract research, development and manufacturing services (CRDMO) for antibody drug conjugates (ADCs) and a wider range of bioconjugate drugs. The firm conducts its businesses through two segments. Research Services on Fee-for-service(FFS) Basis segment providing research services to its customers through FFS contracts. The Research Services on Full-time-equivalent(FTE) Basis segment providing a project team of employees dedicated to the customer's studies for a specific period of time. Based on biopharmaceuticals and small molecule drugs, the Company also provides comprehensive cross-domain services, covering the discovery, process development and good manufacturing practice (GMP) production of bioconjugated drugs, linkers and payloads. The firm conducts its business in domestic and foreign markets.

Intrinsic Value
28.5 HKD
Undervaluation 10%
Intrinsic Value
Price
W

See Also

What is WuXi XDC Cayman Inc's Net Income (Common)?
Net Income (Common)
283.5m CNY

Based on the financial report for Dec 31, 2023, WuXi XDC Cayman Inc's Net Income (Common) amounts to 283.5m CNY.

What is WuXi XDC Cayman Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
121%

Over the last year, the Net Income (Common) growth was 82%. The average annual Net Income (Common) growth rates for WuXi XDC Cayman Inc have been 121% over the past three years .

Back to Top